Oncolytic virotherapy demonstrates promising results for early-stage melanoma patients
23.07.2015

On July 15th Melanoma Research has published online results of a retrospective study on oncolytic virotherapy effectiveness on the overall survival of melanoma patients after surgical excision of the tumour. It was found that stage IB-IIC melanoma patients who were treated with oncolytic virotherapy had an 4.39-6.57 fold lower mortality rate than those treated according to current guidelines by observation.

Adapted ECHO-7 virus immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.